Anzalone Christopher Richard, an insider at Arrowhead Pharmaceuticals Inc (ARWR), purchased 3,841,107 shares of the company on December 28, 2025, at a price of $6.15 per share. This transaction totals $23.62 million, bringing Richard's total holdings in Arrowhead to 3,841,107 shares.
Arrowhead Pharmaceuticals, based in Pasadena, California, focuses on developing medicines that target intractable diseases through gene silencing. The company employs 609 full-time staff and has a market capitalization of $9.2 billion. Arrowhead's innovative therapies leverage RNA interference (RNAi) mechanisms and include a diverse pipeline of 16 clinical-stage investigational medicines across various therapeutic areas, such as cardiometabolic and central nervous system diseases.
The move underscores Richard's confidence in Arrowhead's prospects. Insider buying can be considered a positive indicator, as executives often have access to non-public information about their company's performance. However, investors should approach such transactions cautiously, as motivations can vary widely.
Insider transactions are reported to the SEC, providing transparency into executive sentiment. Analyzing patterns across multiple insiders and time periods can yield more comprehensive insights than isolated transactions alone. Arrowhead's next earnings report is scheduled for August 5, 2026, with an estimated EPS of -$1.31 and revenue of $44.7 million.